Promising KRAS Inhibitor Drug Offers Hope for Pancreatic Cancer Patients

A new drug trial at Penn Medicine’s Abramson Cancer Center is offering hope to patients with advanced pancreatic cancer, including 59-year-old Irene Blair, who was given just six to eight months to live in June. The drug, known as daraxonrasib, belongs to a class of medications that target the KRAS protein, which is implicated in a significant number of aggressive cancers. With only 13% of pancreatic cancer patients surviving five years post-diagnosis, this development represents a critical advancement for a disease that is often diagnosed at later stages.

The potential of daraxonrasib lies in its ability to inhibit proteins that fuel cancer growth. Blair, who started therapy in July as part of a phase 3 trial, has experienced remarkable improvements in her condition. Within three weeks, her pain subsided, and scans showed her tumors were stable or decreasing. By December, her cancer had not progressed, a significant contrast to the debilitating effects of previous chemotherapy, which had left her unable to walk and 35 pounds lighter.

Former Nebraska Senator Ben Sasse recently revealed his stage 4 pancreatic cancer diagnosis, highlighting the urgency of effective treatments for this deadly disease. The increasing pace of drug review by the federal government, based on early clinical trial results, underscores the potential impact of daraxonrasib. In a phase 1 trial involving 38 patients, the drug reportedly doubled survival times for many, extending the average from 7 months to 15.6 months when compared to standard chemotherapy.

The oncologist overseeing Blair’s treatment, Mark O’Hara, emphasized the need for more effective therapies in the field of pancreatic cancer. “For too long, we haven’t had effective therapies beyond just chemotherapy,” he stated. With the advent of KRAS inhibitors, there is renewed optimism in the medical community.

Significant Findings from Clinical Trials

Research into KRAS inhibitors has been ongoing since the protein’s discovery in 1982. Mutated KRAS acts like a “gas pedal” for cancer growth, contributing to uncontrolled cell proliferation in various cancers, particularly pancreatic, lung, and colon cancers. The FDA approved the first KRAS inhibitors for lung cancer in 2021, and now daraxonrasib is among the first to be tested specifically for pancreatic cancer, where nearly 90% of cases involve these mutations.

Initial results from the phase 1 trial show that over 90% of the 83 patients treated experienced a halt in cancer progression. About 30% of participants even saw their tumors shrink. The drug, which patients take as three daily pills at home, presents manageable side effects, with facial rashes being the most common. Other side effects like diarrhea, nausea, and mouth sores can be treated with additional medications, allowing for a better quality of life compared to traditional chemotherapy.

Blair’s journey exemplifies the potential of this groundbreaking therapy. She looks forward to traveling and spending time with family, contemplating life beyond her diagnosis. “You just wonder, ‘Will I be here next year?’” she reflected, emphasizing the emotional toll of living with cancer. As researchers continue to refine and develop treatments targeting KRAS, there is hope that more patients will benefit from these innovative therapies.

The implications of daraxonrasib and similar drugs could reshape the landscape of treatment for pancreatic cancer, offering new avenues for patients who have long faced grim prognoses.